Our company
Technology
Biotech/Pharma
Applications
Resources
Investors
Contact us

Resources

Therapeutic areas

All Autoimmune diseases General Immuno-oncology Infectious diseases News Partnerships Uncategorised

Diseases

Systemic lupus erythematosus (SLE) Sjörgen’s syndrome Systemic sclerosis (SSc) Rheumatoid arthritis (RA)

Checkpoint inhibitors Bispecifics CAR-T CART-NK EarlyCDT Lung Cancer

COVID19 Long-Covid

Filter by type

annual report

autoantibodies

Brochure

cancer

checkpoint inhibitors

Company News

company update

Diagnostics

immunotheraphies

Indeterminate Pulmonary Nodules

Poster

Publication

Webinar

CEO, Martin Gouldstone Q&A with Vox Markets

11 November 2024

CEO, Martin Gouldstone speaks to Proactive about securing three new contracts, the strengthening of the company’s revenue pipeline and commercial momentum.

1 November 2024

Trading Update

31 October 2024

CEO, Martin Gouldstone speaks to Proactive about the company’s progress and continuous traction

10 September 2024

10 September 2024

Advancing Precision Medicine: Insights from BIO2024

4 September 2024

CEO, Martin Gouldstone speaks to Proactive London about the company’s second contract win with Top 10 Pharma company.

3 September 2024

Additional contract win with Top 10 Pharma Company

2 September 2024

CEO Martin Gouldstone, speaks to Vox Markets about the significance of recent $1.5m contract win

US $1.5m Contract Win with Top 10 Pharma Company

Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer.

CEO, Martin Gouldstone speaks to Proactive London about the company’s six month interim results.

Understanding diseases through the lens of the human immune system.

Company Overview
About ImmunoINSIGHTS™
Biomarker Discovery
Targeted Panels & Arrays
Publications
Contact us
Privacy Policy
Terms of Use
Cookies Policy

© Oncimmune Holdings PLC. Registered England and Wales. Number 09818395.